钠-葡萄糖共转运体-2 抑制剂与 2 型糖尿病患者的心血管保护：系统回顾

IF 3.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Research Pub Date : 2024-05-11 DOI:10.1155/2024/9985836

Richard K. Yankah, Eric K. Anku, Vinay Eligar

引用次数: 0

摘要

背景：越来越多的证据表明，钠-葡萄糖共转运体-2（SGLT2）抑制剂在管理 2 型糖尿病（T2DM）患者方面具有积极作用。SGLT2 抑制剂可保护 T2DM 患者免受心血管并发症的影响，而且总体上是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review

Background: Accumulating evidence has demonstrated the positive effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in managing patients with type 2 diabetes mellitus (T2DM). SGLT2 inhibitors protect patients with T2DM from cardiovascular complications and are generally safe.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Diabetes Research ENDOCRINOLOGY & METABOLISM-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

8.40

自引率

2.30%

发文量

152

审稿时长

14 weeks

期刊介绍： Journal of Diabetes Research is a peer-reviewed, Open Access journal that publishes research articles, review articles, and clinical studies related to type 1 and type 2 diabetes. The journal welcomes submissions focusing on the epidemiology, etiology, pathogenesis, management, and prevention of diabetes, as well as associated complications, such as diabetic retinopathy, neuropathy and nephropathy.